Helmholtz Center for Infection Research

Germany

Back to Profile

1-3 of 3 for Helmholtz Center for Infection Research Sort by
Query
Aggregations
Jurisdiction
        United States 2
        Canada 1
Date
2024 1
Before 2020 1
IPC Class
A61K 39/00 - Medicinal preparations containing antigens or antibodies 3
A61K 39/29 - Hepatitis virus 3
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants 3
A61P 31/14 - Antivirals for RNA viruses 3
A61P 37/04 - Immunostimulants 3
See more
Status
Pending 1
Registered / In Force 2
Found results for  patents

1.

Hepatitis C virus immunogenic compositions and methods of use thereof

      
Application Number 18099035
Grant Number 12042536
Status In Force
Filing Date 2023-01-19
First Publication Date 2024-02-22
Grant Date 2024-07-23
Owner
  • The Governors of the University of Alberta (Canada)
  • Helmholtz Center for Infection Research (Germany)
Inventor
  • Houghton, Michael
  • Landi, Abdolamir
  • Guzman, Carlos A.
  • Ebensen, Thomas
  • Hockman, Darren
  • Law, John L.
  • Logan, Michael

Abstract

The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.

IPC Classes  ?

  • A61K 39/29 - Hepatitis virus
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies
  • A61K 39/12 - Viral antigens
  • A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
  • A61P 31/14 - Antivirals for RNA viruses
  • A61P 37/04 - Immunostimulants
  • C01F 11/02 - Oxides or hydroxides
  • C07D 323/00 - Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms
  • C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
  • C07K 14/18 - Togaviridae, e.g. flavivirus, pestivirus, yellow fever virus, hepatitis C virus, japanese encephalitis virus
  • C07K 14/28 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Vibrionaceae (F)
  • C07K 14/33 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Clostridium (G)
  • C07K 14/34 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Corynebacterium (G)
  • C12N 15/86 - Viral vectors

2.

Hepatitis C virus immunogenic compositions and methods of use thereof

      
Application Number 16336732
Grant Number 10881726
Status In Force
Filing Date 2017-10-05
First Publication Date 2019-08-01
Grant Date 2021-01-05
Owner
  • The Governors of the University of Alberta (Canada)
  • Helmholtz Center for Infection Research (Germany)
Inventor
  • Houghton, Michael
  • Landi, Abdolamir
  • Guzman, Carlos A.
  • Ebensen, Thomas
  • Hockman, Darren
  • Law, John L.
  • Logan, Michael

Abstract

The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.

IPC Classes  ?

  • A61K 39/00 - Medicinal preparations containing antigens or antibodies
  • A61K 39/12 - Viral antigens
  • A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
  • A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
  • A61K 39/095 - Neisseria
  • A61K 39/29 - Hepatitis virus
  • A61P 31/14 - Antivirals for RNA viruses
  • A61P 37/04 - Immunostimulants
  • C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
  • C01F 11/02 - Oxides or hydroxides
  • C07D 323/00 - Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms
  • C07K 14/18 - Togaviridae, e.g. flavivirus, pestivirus, yellow fever virus, hepatitis C virus, japanese encephalitis virus
  • C07K 14/28 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Vibrionaceae (F)
  • C07K 14/33 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Clostridium (G)
  • C07K 14/34 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Corynebacterium (G)
  • C12N 15/86 - Viral vectors

3.

HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF

      
Document Number 03038810
Status Pending
Filing Date 2017-10-05
Owner
  • THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (Canada)
  • HELMHOLTZ CENTER FOR INFECTION RESEARCH (Germany)
Inventor
  • Houghton, Michael
  • Guzman, Carlos A.
  • Ebensen, Thomas
  • Landi, Abdolamir

Abstract

The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.

IPC Classes  ?

  • A61K 39/00 - Medicinal preparations containing antigens or antibodies
  • A61K 39/29 - Hepatitis virus
  • A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
  • A61P 31/14 - Antivirals for RNA viruses
  • A61P 37/04 - Immunostimulants
  • C01F 11/02 - Oxides or hydroxides
  • C07D 323/00 - Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms
  • C07K 14/18 - Togaviridae, e.g. flavivirus, pestivirus, yellow fever virus, hepatitis C virus, japanese encephalitis virus
  • C07K 14/28 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Vibrionaceae (F)
  • C07K 14/33 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Clostridium (G)
  • C07K 14/34 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Corynebacterium (G)